BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas. ALS Nexus convenes leading experts from the ALS community, including... Read More

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow... Read More

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused... Read More

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow... Read More

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial... Read More

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association’s 35 th International Symposium on... Read More

BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, and provided recent pipeline and business updates. “We are pleased to be continuing the advancement of ATH-1105 as a potential... Read More

BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD) will be presented at the 17 th Annual Clinical Trials on Alzheimer’s Disease (CTAD)... Read More

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025 Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage... Read More

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s disease or who are APOE4 carriers, fosgonimeton showed a numerically greater treatment effect All biomarkers associated with Alzheimer’s disease pathology showed changes with fosgonimeton treatment consistent with the broad... Read More

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Athira... Read More

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical... Read More

Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration,... Read More

Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint, the Global Statistical Test, designed to measure overall impact on disease Webinar event on Tuesday, June 18 th at 11:30 a.m. ET BOTHELL, Wash., June 12,... Read More

BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dose escalation Phase 1 clinical study evaluating ATH-1105, an oral, small molecule positive... Read More

BOTHELL, Wash., May 29, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in June. Jefferies Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, June 5,... Read More

BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf... Read More

Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support... Read More

BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor Conference Format: Company Presentation Date and Time:... Read More

BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading... Read More

BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease. The original research article, “ Fosgonimeton Attenuates Amyloid-Beta... Read More

BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online. The... Read More

Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and dementia with Lewy bodies Results from exploratory SHAPE Phase 2 trial show encouraging safety and pro-cognitive measures with fosgonimeton treatment and underscore confidence in Phase 2/3 LIFT-AD trial... Read More

Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease; topline data expected in second half of 2024 On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 Strong balance sheet to support innovative pipeline through key inflection points BOTHELL, Wash., Feb. 22, 2024... Read More

BOTHELL, Wash., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research... Read More

Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024 Plans to initiate first-in-human studies of ATH-1105 to treat amyotrophic lateral sclerosis in first half of 2024 BOTHELL, Wash., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical... Read More

Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach focused on HGF modulation for treatment of neurodegenerative diseases BOTHELL, Wash., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage... Read More

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases Cognitive measures in the 40 mg dose group bolster confidence in ongoing Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer’s disease, which is on track to complete enrollment in early 2024 and report topline... Read More

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023. Details are as follows: Sidoti December Small Cap... Read More

BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis (ALS) will be delivered at the... Read More

BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases at the Society for... Read More

Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments for neurodegenerative diseases Expects to complete enrollment of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients by the first quarter of 2024 with topline data expected in... Read More

BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023, in London. Details are as follows: Jefferies London... Read More

New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of motor function Data presented at invitational Northeast ALS Consortium (NEALS) meeting BOTHELL, Wash., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on... Read More

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in October. Goldman Sachs Alzheimer’s Disease Day Format: Panel Presentation Date and Time:... Read More

BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City.... Read More

Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Chief Financial Officer and Chief Business Officer Maintains strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points BOTHELL, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage... Read More

New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß-mediated toxicity In preclinical models, ATH-1105 protects against pathologies common to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) Data presented at the Alzheimer’s Association International Conference in Amsterdam BOTHELL, Wash., July 17, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a... Read More

BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that three poster presentations will be delivered in-person at the upcoming Alzheimer’s Association International Conference (AAIC) 2023, to be held July 16 – 20, 2023, virtually and in... Read More

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences: Jefferies Healthcare Conference Fireside Chat on Wednesday, June 7, 2023, at 8:30 a.m. ET in New... Read More

BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as... Read More

Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term exposure data ATH-1105 significantly prolongs survival and improves motor function in a mouse model of ALS; Strongly supports development as a treatment for ALS Strong balance sheet to support innovative clinical development pipeline in... Read More

BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor conferences: JMP Securities Life Sciences Conference Fireside chat on Monday, May 15, 2023, at 10:30 am ET in New York. Mizuho... Read More

Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer’s disease Preclinical findings with fosgonimeton further elucidate its multimodal effects and continue to support therapeutic potential for Alzheimer’s and Parkinson’s ATH-1105 significantly prolongs survival and improves motor function in a mouse model of ALS; strongly... Read More

Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients including improvements in measures of cognition and plasma biomarkers Oral presentation to report new preclinical research supporting the therapeutic potential of enhancement of HGF/MET pathway with fosgonimeton in neurodegenerative conditions Poster presentation to highlight... Read More

BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related... Read More

On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development of ATH-1105 as a potential clinical candidate for amyotrophic lateral sclerosis Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points BOTHELL, Wash., March... Read More

BOTHELL, Wash., March 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira’s management team will participate in the following upcoming investor conferences: Needham Neurosciences Investor Forum taking place virtually March 15, 2023.... Read More

BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in two upcoming scientific conferences: American Society for Experimental Neurotherapeutics (ASENT) 2023 Annual Meeting, which will be held virtually from Mar.... Read More

BOTHELL, Wash., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of a review paper highlighting the need for novel treatment approaches to address Alzheimer’s disease and the therapeutic potential of fosgonimeton, one of the Company’s... Read More

BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer. “Kevin is a driving force behind our research at Athira. He is instrumental in leading and directing our efforts to... Read More

Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer’s disease is progressing with targeted enrollment completion in mid-2023 and topline data in early 2024 ATH-1105 candidate for amyotrophic lateral sclerosis (ALS) is targeted for IND... Read More

BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and procognitive effects of fosgonimeton (ATH-1017) in preclinical models. The article titled,... Read More

ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS Data adds to the growing body of evidence supporting the potential neuroprotective, anti-inflammatory, and disease-modifying effects of enhancing the HGF/MET neurotrophic system BOTHELL, Wash., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late... Read More